Notice NOT-MH-20-060 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HL-21-003 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seeks highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Applications submitted in response to this bi-phasic, milestone-driven cooperative agreement FOA are expected to propose highly innovative projects with a focus on solutions to widely-recognized issues in the development of safe and effective RM therapies. Of particular interest are projects using RM products that have undergone appropriate product development and pre-clinical studies and have demonstrated readiness to advance into clinical trials. This FOA seeks Phase I and beyond clinical trial applications that present a strong scientific rationale for the proposed clinical trial and a comprehensive scientific and operational plan. Trials must be relevant to the research mission of one or more participating NIH Institutes and Centers and meet the NIH definition of a clinical trial (see NOT-OD-15-015). Applications are expected to include plans for project management, participant recruitment and retention, performance milestones, conduct of the trial, and dissemination of results. Before the time of award and if applicable, successful applicants must obtain an Investigational New Drug (IND) authorization or Investigational New Device Exemption (IDE) approval to administer the product to humans. Successful applicants proposing the use of adult stem cells as a clinical intervention will be asked to make available representative samples of the source stem cell and clinical-grade stem cell-derived product for in-depth and independ

F. Hoffmann-La Roche AG: As an Senior Principal Data Scientist within our Personalized HealthCare function you will work with meaningful data to generate impactful evidence a Switzerland (CH)

Notice NOT-GM-20-028 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: Bioinformatican Location: EMBL-E Cambridge, Cambridgeshire, England

Funding Opportunity RFA-DA-21-013 from the NIH Guide for Grants and Contracts. This funding opportunity announcement invites computational HIV/AIDS research as it relates to NIDAs mission through collaborative research between investigators with experimental expertise related to HIV/AIDS and those with computational proficiency, including scientists from statistics, physics, mathematics, engineering, and computer science. An R01 research project should build on well-established computational strategies (theory, models, and methods) to investigate HIV-related neurocognitive deficits and neuropathogenesis in the context of substance use or substance use disorder (SUD).

F. Hoffmann-La Roche AG: At Roche, we believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate abou Switzerland (CH)

Funding Opportunity PAR-20-223 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Research Experiences

Notice NOT-HL-20-794 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-213 from the NIH Guide for Grants and Contracts. The goal of the National Institute of General Medical Sciences (NIGMS) Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grant (T32) program is to develop a diverse pool of well-trained scientists available to address the Nations biomedical research agenda. Specifically, this funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation.

Notice NOT-HG-20-042 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-225 from the NIH Guide for Grants and Contracts. Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.

Funding Opportunity PAR-20-224 from the NIH Guide for Grants and Contracts. Avenir means future in French, and the Avenir Award Program for Research on Substance Abuse and HIV/AIDS looks toward the future by supporting early stage investigators (ESI) proposing highly innovative studies that address NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html. The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support creative individuals who wish to pursue innovative research at the nexus of substance abuse and HIV/AIDS. The nexus with drug abuse should be clearly described. The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support research approaches, both basic and clinical, which have the potential to benefit substance using populations with or at risk for HIV/AIDS by reducing HIV incidence, improving therapies for HIV, reducing the impact of comorbid conditions, and ultimately, eradicating HIV.

Funding Opportunity PAR-20-221 from the NIH Guide for Grants and Contracts. The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term avant-garde is used to describe highly innovative approaches that have the potential to be transformative. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html. The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.

From £28,000 per annum DOE: CK Group: Natasha Young is recruiting for a Bioinformatician to join a small, dedicated team providing an outsourced service to one of the top ten largest pharmaceutical... Bracknell

Funding Opportunity RFA-HD-21-016 from the NIH Guide for Grants and Contracts. The purpose of this funding announcement is to invite applications to form a research network to conduct multisite clinical studies in pediatric critical care medicine. The Network will be comprised of a Data Coordinating Center (DCC) and at least seven Clinical Sites. The Network is designed to investigate the efficacy of treatment and management strategies to care for critically ill and injured children, as well as to better understand the pathophysiological bases of critical illness and injury in childhood.

Notice NOT-DK-20-032 from the NIH Guide for Grants and Contracts

Notice NOT-DK-20-033 from the NIH Guide for Grants and Contracts

Notice NOT-MH-20-051 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-112 from the NIH Guide for Grants and Contracts